Clinical Trial Update: A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating nivolumab in Class II expressing microsatellite-stable colorectal cancer has completed. Results were posted on 2026-04-22.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: University of Birmingham | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-04-22